BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 26116553)

  • 21. Early anti-TNF/immunomodulator therapy is associated with better long-term clinical outcomes in Asian patients with Crohn's disease with poor prognostic factors.
    Oh EH; Oh K; Han M; Seo H; Chang K; Lee SH; Kim GU; Song EM; Seo M; Lee HS; Hwang SW; Park SH; Yang DH; Kim KJ; Byeon JS; Myung SJ; Yang SK; Ye BD
    PLoS One; 2017; 12(5):e0177479. PubMed ID: 28542298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interventions for prevention of post-operative recurrence of Crohn's disease.
    Doherty G; Bennett G; Patil S; Cheifetz A; Moss AC
    Cochrane Database Syst Rev; 2009 Oct; (4):CD006873. PubMed ID: 19821389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of perianal fistula in Crohn's disease: a systematic review and meta-analysis comparing seton drainage and anti-tumour necrosis factor treatment.
    de Groof EJ; Sahami S; Lucas C; Ponsioen CY; Bemelman WA; Buskens CJ
    Colorectal Dis; 2016 Jul; 18(7):667-75. PubMed ID: 26921847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn's Disease.
    Barber GE; Yajnik V; Khalili H; Giallourakis C; Garber J; Xavier R; Ananthakrishnan AN
    Am J Gastroenterol; 2016 Dec; 111(12):1816-1822. PubMed ID: 27596696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection.
    Regueiro M; Feagan BG; Zou B; Johanns J; Blank MA; Chevrier M; Plevy S; Popp J; Cornillie FJ; Lukas M; Danese S; Gionchetti P; Hanauer SB; Reinisch W; Sandborn WJ; Sorrentino D; Rutgeerts P;
    Gastroenterology; 2016 Jun; 150(7):1568-1578. PubMed ID: 26946343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complications in surgery for Crohn's disease after preoperative antitumour necrosis factor therapy.
    Myrelid P; Marti-Gallostra M; Ashraf S; Sunde ML; Tholin M; Oresland T; Lovegrove RE; Tøttrup A; Kjaer DW; George BD
    Br J Surg; 2014 Apr; 101(5):539-45. PubMed ID: 24615529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Direct retrospective comparison of adalimumab and infliximab in preventing early postoperative endoscopic recurrence after ileocaecal resection for crohn's disease: results from the MULTIPER database.
    Kotze PG; Yamamoto T; Danese S; Suzuki Y; Teixeira FV; de Albuquerque IC; Saad-Hossne R; de Barcelos IF; da Silva RN; da Silva Kotze LM; Olandoski M; Sacchi M; Yamada A; Takeuchi K; Spinelli A
    J Crohns Colitis; 2015 Jul; 9(7):541-7. PubMed ID: 25820017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of Anti-Tumor Necrosis Factors and Anti-Integrins in the Treatment of Crohn's Disease.
    Shivashankar R; Pardi DS
    Gastroenterol Clin North Am; 2017 Sep; 46(3):589-601. PubMed ID: 28838417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevention of postoperative recurrence of Crohn's disease.
    van Loo ES; Dijkstra G; Ploeg RJ; Nieuwenhuijs VB
    J Crohns Colitis; 2012 Jul; 6(6):637-46. PubMed ID: 22398096
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
    Sands BE; Feagan BG; Rutgeerts P; Colombel JF; Sandborn WJ; Sy R; D'Haens G; Ben-Horin S; Xu J; Rosario M; Fox I; Parikh A; Milch C; Hanauer S
    Gastroenterology; 2014 Sep; 147(3):618-627.e3. PubMed ID: 24859203
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn's disease.
    Qiu Y; Chen BL; Mao R; Zhang SH; He Y; Zeng ZR; Ben-Horin S; Chen MH
    J Gastroenterol; 2017 May; 52(5):535-554. PubMed ID: 28275925
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: a prospective, two-year, single center, pilot study.
    Papamichael K; Archavlis E; Lariou C; Mantzaris GJ
    J Crohns Colitis; 2012 Oct; 6(9):924-31. PubMed ID: 22424843
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mucosal expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor-α in Crohn's disease in deep remission under treatment with anti-TNFα antibodies.
    Tursi A; Elisei W; Principi M; Inchingolo CD; Nenna R; Picchio M; Giorgio F; Ierardi E; Brandimarte G
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):261-5. PubMed ID: 25267953
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG; Nieminen U; Sipponen T; Turunen U; Arkkila P; Färkkilä M
    Scand J Gastroenterol; 2013 May; 48(5):543-51. PubMed ID: 23477356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Surgery for Crohn's disease and anti-TNF agents: the changing scenario.
    Sorrentino D; Fogel S; Van den Bogaerde J
    Expert Rev Gastroenterol Hepatol; 2013 Nov; 7(8):689-700. PubMed ID: 24161133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.
    Gisbert JP; Marín AC; McNicholl AG; Chaparro M
    Aliment Pharmacol Ther; 2015 Apr; 41(7):613-23. PubMed ID: 25652884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of post-operative recurrence of Crohn's disease.
    Vaughn BP; Moss AC
    World J Gastroenterol; 2014 Feb; 20(5):1147-54. PubMed ID: 24574791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Certolizumab pegol for the management of Crohn's disease in adults.
    Rivkin A
    Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study.
    Zorzi F; Zuzzi S; Onali S; Calabrese E; Condino G; Petruzziello C; Ascolani M; Pallone F; Biancone L
    Aliment Pharmacol Ther; 2012 Jun; 35(12):1397-407. PubMed ID: 22519466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of anti-tumor necrosis factor alpha agents on postoperative anastomotic complications in Crohn's disease: a systematic review.
    El-Hussuna A; Krag A; Olaison G; Bendtsen F; Gluud LL
    Dis Colon Rectum; 2013 Dec; 56(12):1423-33. PubMed ID: 24201398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.